{"id":5087,"date":"2019-12-03T08:00:10","date_gmt":"2019-12-03T07:00:10","guid":{"rendered":"https:\/\/www.bm-t.de\/v4\/2020\/10\/08\/neurocare-group-secures-investment-from-bmt-to-fund-next-growth-stage\/"},"modified":"2020-11-03T14:38:58","modified_gmt":"2020-11-03T13:38:58","slug":"neurocare-group-secures-investment-from-bmt-to-fund-next-growth-stage","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2019-en\/neurocare-group-secures-investment-from-bmt-to-fund-next-growth-stage\/","title":{"rendered":"neuroCare Group secures investment from bm|t to fund next growth stage"},"content":{"rendered":"<div>neuroCare\u00b4s mis\u00adsion is to empower clin\u00adi\u00adcians with an evi\u00addence-based approach to inte\u00adgrate neu\u00adro\u00admod\u00adu\u00adla\u00adtion tech\u00adniques into clin\u00adi\u00adcal prac\u00adtice. neu\u00adro\u00adCare per\u00adson\u00adalises treat\u00adment fol\u00adlow\u00ading a detailed assess\u00adment and hence is able to achieve opti\u00admal indi\u00advid\u00adual out\u00adcomes employ\u00ading sci\u00aden\u00adtif\u00adi\u00adcally proven pro\u00adto\u00adcols. For exam\u00adple, neuroCare\u2019s assess\u00adment analy\u00adses sleep and cir\u00adca\u00addian rhythm as much as psy\u00adcho-diag\u00adnos\u00adtic, genetic and other bio\u00admark\u00aders in a truly holis\u00adtic man\u00adner. This approach empow\u00aders clin\u00adi\u00adcians to pro\u00advide per\u00adson\u00adalised and med\u00adica\u00adtion-free ther\u00adapy that truly addresses the root causes by rewiring the patient\u2019s brain with pos\u00adi\u00adtive emo\u00adtional and behav\u00adioural pat\u00adterns for the long term. neu\u00adro\u00adCare is ver\u00adti\u00adcally inte\u00adgrated, oper\u00adat\u00ading its own Clin\u00adics as well as pro\u00advid\u00ading its tech\u00adnolo\u00adgies, Stan\u00addard Oper\u00adat\u00ading Pro\u00adce\u00addures, ser\u00advices and edu\u00adca\u00adtion to its inhouse and third party clin\u00adics through its Solu\u00adtions divi\u00adsion. Within the Solu\u00adtions divi\u00adsion, neu\u00adro\u00adCad\u00ademy pro\u00advides Train\u00ading &amp; Super\u00advi\u00adsion and neu\u00adro\u00adConn pro\u00advides neu\u00adro\u00admod\u00adu\u00adla\u00adtion tech\u00adnol\u00adogy. These key build\u00ading blocks enable neu\u00adro\u00adCare to sup\u00adport a grow\u00ading net\u00adwork of clin\u00adi\u00adcians. The ori\u00adgin of neuroCare\u2019s Solu\u00adtions divi\u00adsion lies in neu\u00adro\u00adConn, based in Th\u00fcrin\u00adgen, Ger\u00admany. At this loca\u00adtion, the com\u00adpany con\u00adducts its R&amp;D in close co\u00f6per\u00ada\u00adtion with the Uni\u00adver\u00adsity of Ilme\u00adnau and man\u00adu\u00adfac\u00adtures its core soft\u00adware and devices. neu\u00adro\u00adCare is focused on rolling out its strong busi\u00adness model glob\u00adally by sig\u00adnif\u00adi\u00adcantly increas\u00ading its net\u00adwork of inhouse and third party clin\u00adics.&nbsp; The com\u00adpany cur\u00adrently has 16 clin\u00adics and is primed for rapid growth in the years to come.&nbsp; Longer term the com\u00adpany is tar\u00adget\u00ading an IPO to fund its global expan\u00adsion, and now the com\u00adpany has signed an invest\u00adment agree\u00adment with bm|t (beteili\u00adgungs\u00adman\u00adage\u00adment Th\u00fcrin\u00adgen), an insti\u00adtu\u00adtional investor. Accord\u00ading to this agree\u00adment, bm|t will become an anchor investor and help fund the next stage of the company\u00b4s growth by invest\u00ading up to 50% of the required cap\u00adi\u00adtal. Given neuroCare\u00b4s strong pres\u00adence in Th\u00fcrin\u00adgen, it was a nat\u00adural fit to add bm|t as an investor. bm|t is the pre\u00admier investor in the state of Th\u00fcrin\u00adgen and has a wealth of life sci\u00adence invest\u00ading expe\u00adri\u00adence, includ\u00ading invest\u00adments in mul\u00adti\u00adple pub\u00adlicly-traded health\u00adcare com\u00adpa\u00adnies. Kevin Reeder, bm|t\u00b4s CEO, said of the company\u00b4s invest\u00adment in neu\u00adro\u00adCare, \u201cWe could not be more pleased to have invested in neu\u00adro\u00adCare. We believe strongly in the company\u00b4s lead\u00ader\u00adship and vision and see a straight-line path for the com\u00adpany to become a global leader as a provider of high-qual\u00adity men\u00adtal health and per\u00adfor\u00admance solu\u00adtions.\u201d Tom Mechter\u00adsheimer, neuroCare\u00b4s founder and Exec\u00adu\u00adtive Chair, con\u00adcluded by stat\u00ading that \u201cneu\u00adro\u00adCare is dri\u00adving the future of man\u00adag\u00ading men\u00adtal health and cog\u00adni\u00adtive per\u00adfor\u00admance with per\u00adson\u00adalised, opti\u00admal and mea\u00adsur\u00adable out\u00adcomes for every patient or client.\u201d<\/div>\n<h3><strong>About <a href=\"http:\/\/www.neurocaregroup.com\" target=\"_blank\" rel=\"noopener noreferrer\">neuroCare Group<\/a><\/strong><\/h3>\n<div>The neu\u00adro\u00adCare Group (nCG) is a fast-grow\u00ading, ver\u00adti\u00adcally-inte\u00adgrated com\u00adpany pro\u00advid\u00ading a holis\u00adtic and per\u00adson\u00adalised approach for improv\u00ading men\u00adtal health and per\u00adfor\u00admance. By inte\u00adgrat\u00ading neu\u00adro\u00admod\u00adu\u00adla\u00adtion tech\u00adnol\u00adogy with best process and work\u00ading in syn\u00adergy with the clin\u00adi\u00adcians, neu\u00adro\u00adCare is achiev\u00ading best-in-class clin\u00adi\u00adcal out\u00adcome for patients. nCG is employ\u00ading 130 peo\u00adple serv\u00ading around 1500 patients per annum in cur\u00adrently 16 clin\u00adics in Aus\u00adtralia, the Nether\u00adlands and the USA, whilst its tech\u00adnol\u00adogy solu\u00adtions back\u00adbone is in Germany.<\/div>\n<h3><strong>About <a href=\"https:\/\/www.bm-t.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">bm\u2011t<\/a><\/strong><\/h3>\n<div>Erfurt-based, beteili\u00adgungs\u00adman\u00adage\u00adment Th\u00fcrin\u00adgen (bm|t) \u2013 a sub\u00adsidiary of the Th\u00fcrin\u00adgen Devel\u00adop\u00adment Bank, is the first address for invest\u00adments in Th\u00fcrin\u00adgen, Ger\u00admany.&nbsp; bm|t cur\u00adrently man\u00adages eight invest\u00adment funds with a total vol\u00adume of 320M EUR. bm|t invests in inno\u00adv\u00ada\u00adtive com\u00adpa\u00adnies with strong growth poten\u00adtial across all sec\u00adtors and all phases of the cor\u00adpo\u00adrate lifecycle.<\/div>\n","protected":false},"excerpt":{"rendered":"<p>neuroCare\u00b4s mis\u00adsion is to empower clin\u00adi\u00adcians with an evi\u00ad\u00addence-based approach to inte\u00adgrate neu\u00adro\u00admod\u00adu\u00adla\u00adtion tech\u00adniques into clin\u00adi\u00adcal prac\u00adtice. neu\u00adro\u00adCare per\u00adson\u00adalises treat\u00adment fol\u00adlow\u00ading a detailed assess\u00adment and hence is able to achieve opti\u00admal indi\u00advid\u00adual out\u00adcomes employ\u00ading sci\u00aden\u00adtif\u00adi\u00adcally proven pro\u00adto\u00adcols. For exam\u00adple, neuroCare\u2019s assess\u00adment analy\u00adses sleep and cir\u00adca\u00addian rhythm as much as psy\u00ad\u00adcho-diag\u00adnos\u00adtic, genetic and other bio\u00admark\u00aders&nbsp;in&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":5210,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[148],"tags":[],"class_list":["post-5087","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2019-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/5087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=5087"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/5087\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/5210"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=5087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=5087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=5087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}